Karyn Schmidt

Karyn Schmidt, Ph.D. has extensive experience in the field of biochemistry and molecular biology. Karyn has held various roles in prestigious institutions such as Alnylam Pharmaceuticals, Dana-Farber Cancer Institute, and Harvard Medical School. Their work has focused on the RNAi pathway, long non-coding RNA in cancer, and investigating toxin regions in bacteria. Karyn holds a Ph.D. in Biochemistry from the University of Rochester School of Medicine and Dentistry, and a B.S. in Biochemistry from the University of Rochester.